Northwell Cancer Institute has partnered with Cancer Hope Network to provide personalized peer mentorship for cancer patients by connecting them with specially trained survivors who have navigated similar cancer diagnoses.
Positive topline results from the registrational ChonDRAgon study investigating ozekibart (INBRX-109) as a single agent versus placebo in patients with advanced or metastatic, unresectable chondrosarcoma were recently reported.
Using intraoperative radiation to eliminate pancreatic cancer cells that have spread to areas around the pancreas, investigators at Johns Hopkins have been able to reduce the recurrence rate around the pancreas to 5%.
Federally funded research in mice showed that neurons regulate osteosarcoma progression, suggesting that inhibiting nerve signaling might improve patient outcomes.
Scientists face limitations in determining the results of drug effectiveness, as well as ensuring even distribution among all cancer cells because of the highly compact nature of tumors. Researchers are working to change that by giving chemotherapy drugs a kind of chemical “signal” to track them inside cells.
Mayo Clinic researchers have discovered why certain breast cancers might not respond to an important new class of therapeutics called antibody drug conjugates.
Mayo Clinic researchers have identified a specific immune cell that can be targeted to give a boost to standard immunotherapies for cancer. Two research teams, working collaboratively but using distinct approaches, found that “first-responder” immune cells known as myeloid cells can be manipulated to enhance the activity of tumor-killing T cells.
In a new draft guidance, FDA proposes major updates to simplify biosimilarity studies and reduce unnecessary clinical testing.
The European Commission approved Keytruda (pembrolizumab), an anti-PD-1 therapy, as a monotherapy for the treatment of resectable locally advanced head-and-neck squamous cell carcinoma as neoadjuvant treatment, continued as adjuvant treatment in combination with radiation therapy with or without concomitant cisplatin and then as monotherapy in adults whose tumors express PD-L1 with a Combined Positive Score ≥1.
Recent results from the PATHFINDER 2 study showed that the addition of GRAIL’s multi-cancer detection test to standard screening led to a seven-fold increase in cancers detected within a year, the company said.
